ReviewClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2020
Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.
Review in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 606 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role of Blood Lactate Level in Prediction of Outcome of Cirrhotic Patients at The Intensive Care Unit
Technical Development and Clinical Validation of a Comprehensive One-stop Shop Assessment of the Cirrhotic Liver With [68Ga]Ga-PSMA-11 PET/MRI
Who cites it
606 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Association between periodontitis and non-alcoholic fatty liver disease in community-dwelling adults: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- The Affordable Care Act Improves Access, Survival, and Racial Disparities of Patients With Liver Disease: A Systematic Review.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2026Pooled it
- Prevalence and clinical characteristics of concurrent chronic hepatitis B and fatty liver disease in China: a systematic review and meta-analysis.BMC public health · 2025Pooled it
- Exercise and nutrition interventions for sarcopenia in cirrhosis: a systematic review and network meta-analysis of randomized controlled trials.European journal of clinical nutrition · 2025Pooled it
- Adiponectin as a biomarker in liver cirrhosis-A systematic review and meta-analysis.European journal of clinical investigation · 2025Pooled it
- Standard-Dose Ursodeoxycholic Acid Improves Biochemical Liver Function and Fibrosis in Chronic Liver Disease: Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.Journal of Korean medical science · 2026Trial
- Evaluating a transdisciplinary supportive care model for advanced liver disease: Results of thePalliative & supportive care · 2026Trial
- Noninvasive Evaluation of Prolonged-Release Pirfenidone in Compensated Liver Cirrhosis. ODISEA Study, a Randomised Trial.Liver international : official journal of the International Association for the Study of the Liver · 2025Trial
- Microbial cues and T cell immunity: deciphering their interactions in chronic liver disease.Experimental & molecular medicine · 2026Review
- Article
- An artificial intelligence-augmented electrocardiogram model can detect undiagnosed chronic liver disease, but can this be applied in primary care?Hepatobiliary surgery and nutrition · 2026Article
- Deciphering the Genetic Underpinnings of Liver Cirrhosis-Heart Failure Comorbidity Through Multi-Omics: CRIM1 as a Key Endothelial Mediator.International journal of molecular sciences · 2026Article
- Review
- Special Issue "Liver Fibrosis: Molecular Pathogenesis, Diagnosis and Treatment".International journal of molecular sciences · 2026Article
- Large Language Models for Heterogeneous Data Mining in Liver Disease: Framework Development and Retrospective Validation Study.Journal of medical Internet research · 2026Article
- National and state-level trends in digestive diseases in the United States, 1990 to 2021.Proceedings (Baylor University. Medical Center) · 2026Article
- Understanding the gap and addressing disparities in US digestive health.Proceedings (Baylor University. Medical Center) · 2026Article
- Article
- Psychological Burden Among Informal Caregivers of Cirrhosis and Liver Transplant Patients: A Cross-Sectional Study Using the Burden Scale for Family Caregivers.Journal of evaluation in clinical practice · 2026Article
- Palliative Care in Patients with Liver Cirrhosis: A Scoping Review of Identification, Interventions, and Implementation Barriers and Facilitators.Healthcare (Basel, Switzerland) · 2026Review
546 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
BACKGROUND &
aimsAccurate estimates for the contemporary burden of chronic liver disease (CLD) are vital for setting clinical, research, and policy priorities. We aimed to review the incidence, prevalence, and mortality of CLD and its resulting complications, including cirrhosis and hepatocellular carcinoma (HCC).
methodsWe reviewed the published literature on the incidence, prevalence, trends of various etiologies of CLD and its resulting complications. In addition, we provided updated data from the Centers for Disease Control and Global Burden of Disease Study on the morbidity and mortality of CLD, cirrhosis, and hepatocellular carcinoma (HCC). Lastly, we assessed the strengths and weaknesses of available sources of data in hopes of providing important context to these national estimates of cirrhosis burden.
resultsAn estimated 1.5 billion persons have CLD worldwide and the age-standardized incidence of CLD and cirrhosis is 20.7/100,000, a 13% increase since 2000. Similarly, cirrhosis prevalence and mortality has increased in recent years in the United States. The epidemiology of CLD is shifting, reflecting implementation of large-scale hepatitis B vaccination and hepatitis C treatment programs, the increasing prevalence of the metabolic syndrome, and increasing alcohol misuse.
conclusionsThe global burden of CLD and cirrhosis is substantial. Although vaccination, screening, and antiviral treatment campaigns for hepatitis B and C have reduced the CLD burden in some parts of the world, concomitant increases in injection drug use, alcohol misuse, and metabolic syndrome threaten these trends. Ongoing efforts to address CLD-related morbidity and mortality require accurate contemporary estimates of epidemiology and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.